ClinicalTrials.gg
Not yet recruitingNCT06590090Updated Dec 9, 2025

Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

A Phase 2 interventional study of Natrunix 400 mg and Placebo in Rheumatoid Arthritis, sponsored by XBiotech, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by XBiotech, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Planned enrollment
63rd of 113
108 · median 130
Started
2026
the only one that year
Phase 2
10 of 113
2 open now
Registered
110th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 63rd largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 2, and was the 110th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Approximately 108 subjects will be randomized in 2 arms in 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).

The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.

Read the detailed description

Number of Planned Subjects: Approximately 108 subjects within 2 arms randomized 2:1 [400 mg Natrunix + MTX weekly (n=72) or placebo + MTX weekly arms (n=36)].

Study Duration: The study will last for a maximum of 33 weeks, including: a screening period of up to 4 weeks, a 14-week double-blinded treatment phase followed by a 14-week open label extension phase and one-week follow-up.

Study Design: Subjects will be randomized into the study in a 2:1 ratio to receive weekly subcutaneous injections of either 400mg Natrunix + MTX weekly or placebo + MTX weekly for 14 weeks. At the week 14 visit subjects in both arms will undergo a safety follow up visit OR begin receiving biweekly subcutaneous injections of 400mg Natrunix for 14 weeks as part of an Open Label Extension (OLE).

Subjects will undergo a preliminary assessment for study eligibility. Subjects who meet pre-screening requirements may then provide informed consent to acknowledge understanding of and accept enrollment into the clinical study. Subjects enrolled in the study will be taking concomitant methotrexate, have a diagnosis of moderate to severe RA according to 2010 ACR/EULAR classification criteria and have ≥6 swollen joints (based on DAS28), ≥6 tender joints (based on DAS28) and DAS-ESR > 3.2.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weight > 40 kg
  2. Diagnosis of moderate to severe RA according to 2010 ACR/EULAR classification criteria.
  3. Patients must be methotrexate-inadequate responders.

    a. Persistent moderate to severe RA disease activity (i.e., criteria #2 above) despite ongoing treatment with MTX.

  4. Meets the following minimum disease activity criteria at screening: ≥6 swollen joints (based on DAS28) and ≥6 tender joints (based on DAS28) and DAS-ESR (Erythrocyte Sedimentation Rate) > 3.2.
  5. Subject must be receiving MTX treatment at a dosage of 10-25 mg/week for a minimum of 12 weeks; and be receiving a stable dose of MTX for >4 weeks preceding randomization. Subjects must also be in principle agreement to remain at the pre-randomization stable dose of MTX for the entire duration of the study. Subjects must also be willing to take a minimum of 5 mg folic acid/folinic acid per week for the duration of the study.
  6. Subjects must have discontinued all csDMARDs (excluding MTX) for at least 4 weeks or 5 half-lives prior to enrollment, whichever is longer.
  7. Subjects taking regular NSAIDs, Acetaminophen, oral (\<10mg/day prednisone equivalent), and inhaled corticosteroids must be on a stable dose for 2 weeks prior to enrollment.
  8. Subjects must have discontinued high potency opioids (oxycodone, fentanyl, etc.) for at least 4 weeks prior to enrollment.
  9. Male or female, at least 18 years of age, willing to provide , able to attend all clinic visits, comply with study-related procedures and able to understand and complete study-related questionnaires.
  10. Patients must provide at least 7 consecutive days of NRS-pain data in the subject's diary prior to the baseline visit. The NRS pain diary should ideally be completed for the 7 days immediately prior to Visit 1 (when the first dose of test drug is administered). Subjects may record more than 7 days of pain records in the diary for their baseline. At least seven consecutive days of pain diary are necessary to be eligible for enrollment in the study.
  11. Peripheral blood CD19+ cell count recovery to >10 cells/uL or >1% of total lymphocyte count (Required only for subjects who have received a Rituximab (or anti-CD20 biosimilar) infusion within 12 months prior to enrollment).
  12. Female patients of must consent to undergo a serum pregnancy test at enrollment, and urine pregnancy tests at each visit after screening. Women of non-childbearing potential include those considered to have a medical history that indicates that pregnancy is not a reasonable risk, including women and those with a history of hysterectomy or surgically sterilized.
  13. In case of female patients of childbearing potential, willingness to use one method of of high efficacy during the entire study period. These methods can include but not limited to hormonal contraceptives, intrauterine devices, condoms, diaphragms, etc.
  14. Males participating in this clinical research study should not get a sexual partner pregnant during their participation in this research study as the effect of the study drug on sperm is not known. Male contraception methods can include but are not limited to mechanical methods (e.g., abstinence, non-vaginal intercourse), contemporary methods comprising barrier methods (e.g., spermicide, condom, sponge, diaphragm and cervical cap) and vasectomy.

Exclusion criteria

Exclusion Criteria:

  1. History of treatment with Natrunix for any reason.
  2. Any active, chronic, or recurrent infections. (e.g., ongoing bacterial, viral, or fungal infection).
  3. Comorbid severe psychiatric illness and/or complicated social situations that would limit compliance with study requirements.
  4. Patients with a positive result of TB test (QuantiFERON-TB Gold (QFT) at screening unless the patients can present a documentation of completion of TB treatment course by the local Health Department and a clear chest x-ray at enrollment.
  5. Patients who have failed more than 1 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) regimen (excluding Methotrexate monotherapy) due to inefficacy at any point prior to enrollment.
  6. Patients who have received any biological therapy including anakinra, rilonacept, canakinumab, adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, and biosimilars at any point prior to enrollment.
  7. Treatment with JAK inhibitors at any point prior to enrollment.
  8. Patients who have received treatment with Injectable within 8 weeks prior to enrollment.
  9. therapy administered within a time interval less than at least 5 half-lives of the investigational agent prior to the first scheduled day of dosing in this study.
  10. Pregnant or breastfeeding patients.
  11. Patients with current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within a year prior to enrollment.
  12. Uncontrolled heart disease, including Class III or IV congestive heart failure, ventricular arrhythmia, uncontrolled blood pressure (defined as ≥ 160/100 mm Hg), or unstable angina.
  13. laboratory abnormalities, including:

    1. \<9.0 g/dL
    2. White blood cell counts \< 4000/mm3
    3. (ANC) \<1500/mm3
    4. count \<100,000/mm3
    5. Absolute lymphocyte count (ALC) \<500/mm3
    6. \<45 mL/min
    7. (ALT) >1.5x lab (ULN)
    8. Aspartate Aminotransferase (AST) >1.5x lab upper limit of normal (ULN)
    9. >1.5x lab upper limit of normal (ULN)
  14. Major surgery (including joint surgery) within 3 months of baseline.
  15. Patients who have suffered severe trauma or fracture within 4 weeks of baseline.
  16. Evidence of active , , or infection.

    1. Patients positive for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody status) are excluded.
    2. Patients who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on a subsequent sample will be eligible to participate. Patients who are positive for Hepatitis C antibody and have a positive result for the HCV when the Hepatitis C RNA-PCR assay is performed on the subsequent sample will not be eligible to participate.
  17. Any other concomitant disease, disorder, or condition that could interfere with the interpretation of study endpoints, or the patient's ability to participate in and complete the study, including but not limited to:

    1. Coexisting diseases which are for MTX treatment.
    2. Cardiovascular, renal, pulmonary, gastrointestinal, or nervous system disorders that, in the opinion of the principal investigator and/or study medical monitor, make the patient not suitable for enrollment.
    3. Concurrent disease excluding Sjogren's syndrome secondary to rheumatoid arthritis.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    400mg Natrunix + MTX weekly

    Subjects will receive 400mg Natrunix and MTX weekly

    Biological: Natrunix 400 mg · Drug: Methotrexate (MTX)

  • Experimental
    Placebo+ MTX weekly

    Subjects will receive placebo and MTX weekly

    Drug: Placebo · Drug: Methotrexate (MTX)

Interventions

  • BiologicalNatrunix 400 mg

    The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human. Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0.

    Also known as: methotrexate

  • DrugPlacebo

    Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product

  • Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.

06

What researchers measure

Primary outcomes

  1. ACR 20 response

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 14 weeks from baseline

Secondary outcomes

  1. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 14 weeks from baseline

  2. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Time frame: at 14 weeks from baseline

  3. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Time frame: at 14 weeks from baseline

  4. ACR 70 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  5. ACR 20 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 2, 4, 8 and 12 weeks from baseline

  6. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 2, 4, 8 and 12 weeks from baseline

  7. Mean change in HAQ-DI score

    HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  8. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Time frame: at 2, 4, 8 and 12 weeks from baseline

  9. Mean change in RAPID-3 score

    The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (\>12 = high; 6.1-12 = moderate; 3.1-6 = low; \< 3 = remission).

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  10. Mean change in the PGA score

    A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  11. Mean change in the EGA score

    The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  12. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Time frame: at 2, 4, 8, and 12 weeks from baseline

  13. Mean change in the CDAI score

    The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (\>22).

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  14. Mean change in DAS28-ESR score

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease: \<2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity \>5.1: High disease activity

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  15. Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease. The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis

    Time frame: at 2, 4, 8, 12 and 14 weeks from baseline

  16. Occurence of AEs and SAEs in subjects during the trial

    Subjects will be monitored for any adverse events or serious adverse reactions due to study drug

    Time frame: until 28 weeks from baseline

  17. Any abnormality in Physical examination will be monitored

    Physical examination is the process of evaluating objective anatomic findings through the use of observation, palpation, percussion, and auscultation.

    Time frame: until 28 weeks from baseline

  18. Any clinically significant changes in vital signs from normality will be assessed

    Vital signs are measurements of the body's most basic functions, such as breathing rate, heart rate, body temperature, and blood pressure.

    Time frame: until 28 weeks from baseline

  19. Any abnormal laboratory tests will be monitored

    Laboratory test is a medical procedure that involves testing a sample of blood, urine, or other substance from the body.

    Time frame: until 28 weeks from baseline

  20. ACR 20 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 22 and 28 OLE weeks

  21. ACR 50 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 22 and 28 OLE weeks

  22. ACR 70 response rate

    The American College of Rheumatology (ACR) response criteria for rheumatoid arthritis (RA) are used to measure how effective study drug is in this study.

    Time frame: at 22 and 28 OLE weeks

  23. Mean change in number of swollen and tender joints based on 66/68-joint count

    Subject's tender and swollen joint will be counted by investigators

    Time frame: at 22 and 28 OLE weeks

  24. Mean change in NRS-pain score

    Subjects will rate the pain score everyday between 7-10pm, where 0 is no pain and 10 is maximum pain

    Time frame: at 22 and 28 OLE weeks

  25. Mean change in HAQ-DI score

    HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI): This questionnaire is used in this study which has 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities subjects will be assessed on. In each section, 0 represents without any difficulty and 3 represents task cannot be done at all. In each section, if one question is scored 1 and another 2, then the score for the section is 2. If an aid or device is used or if help is required from another individual, then the minimum score for that section is 2. If the section score is already 2 or more then no modification is made. If any task is not applicable, it can be left blank by the subject.

    Time frame: at 22 and 28 OLE weeks

  26. Mean change in RAPID-3 score

    The RAPID3 (Routine Assessment of Patient Index Data 3) is an index of data set measures to assess disease severity. Each measure is scored 0 to 10, for a total of 30. Higher RAPID3 scores correlate with higher disease severity (\>12 = high; 6.1-12 = moderate; 3.1-6 = low; \< 3 = remission).

    Time frame: at 22 and 28 OLE weeks

  27. Mean change in the PGA score

    A patient global assessment (PGA) score is a single question with a 0 to 10 response. Higher scores represent a higher level of disease activity or a worse global health.

    Time frame: at 22 and 28 OLE weeks

  28. Mean change in the EGA score

    The evaluator global assessment (EGA) score is a single question used to assess how well a patient is doing regarding the status of a disease. This is scored 0-10, higher scores represent worse activity.

    Time frame: at 22 and 28 OLE weeks

  29. Mean change in the CDAI score

    The Clinical Disease Activity Index (CDAI) is a composite index for assessing disease activity, it is based on the count of swollen/tender joint count of 28 joints along with patient and evaluator global assessments. The CDAI has a range of 0 -76 and can be classified as: remission (≤2.8), low disease activity (2.9-10), moderate disease activity (10.1-22), and high disease activity (\>22).

    Time frame: at 22 and 28 OLE weeks

  30. Mean change in DAS28-ESR score

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease: \<2.6: Remission 2.6-3.2: Low disease activity 3.2-5.1: Moderate disease activity \>5.1: High disease activity

    Time frame: at 22 and 28 OLE weeks

  31. Percentage of patients with Low Disease Activity (DAS-ESR <3.2; CDAI > 2.8 & ≤ 10)

    The Disease Activity Score (DAS28) with (Erythrocyte Sedimentation Rate) is a calculator for rheumatoid arthritis that measures disease activity on a scale of 0-10. A higher score indicates more active disease. The Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis determines severity of rheumatoid arthritis

    Time frame: at 22 and 28 OLE weeks

  32. Assessment of Maximum Plasma Concentration

    Blood samples will be collected from subjects. Maximum Plasma Concentration (Cmax) measurement of Natrunix will be performed in all enrolled participants.

    Time frame: at baseline (pre-treatment) until week 14

  33. Number of participants with Anti-Drug Antibodies

    Blood samples will also be used to test for the presence of treatment emergent anti-drug antibodies (ADA) against Natrunix. XBiotech has developed an ELISA method to perform quantitative and qualitative measurements of ADA.

    Time frame: at baseline (pre-treatment) until week 14

  34. ECG QTc interval

    An electrocardiogram (ECG or EKG) is a non-invasive test that records the cardiac electrical activity. QTc(ms) value will be collected along with a clinical interpretation. A normal QTc interval on an ECG, is generally considered to be between 350 and 450 milliseconds (ms) for men and 360 to 460 ms for women. Any abnormalities in ECG will be recorded during study from baseline.

    Time frame: until 28 weeks from baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 6 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Sep 19, 2024
StartEst.
Jul 15, 2026
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06590090
Lead sponsor
XBiotech, Inc.
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jul 15, 2026 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

Haritha Pallapotu
Contact
hpallapotu@xbiotech.com
512-386-2992
Norma Gonzalez
Contact
ngonzalez@xbiotech.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion